Isomorphic Labs
PrivateLast Round
Series B
May 12, 2026
Est. Valuation
$17.5B
Total Funding Raised
$2.94B
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Isomorphic Labs is a biotechnology company that uses an AI-first approach to reimagine the drug discovery process.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Isomorphic Labs Comparables
Compare Isomorphic Labs with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insilico Medicine | 84% | |
| Generate Biomedicines | 83% | |
| BenevolentAI | 81% |
For institutional investors. Book with your work email.
Isomorphic Labs Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 12, 2026 | ||||
| Series A | Mar 31, 2025 | ||||
| Corporate Funding | Sep 18, 2024 | ||||
| Spinoff | Nov 4, 2021 |
For institutional investors. Book with your work email.
Secondary Market Activity
Bids, offers, and trades by month
| Operation | Date | Price | Size | Share Class | Structure |
|---|---|---|---|---|---|
OFFER | |||||
BID | |||||
OFFER |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Isomorphic Labs Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UK Department for Science, Innovation and Technology | Series B |
| Temasek | Series B |
| GV | Series B, Series A |
| Thrive Capital | Series B, Series A |
| CapitalG | Series B |
| MGX | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
Open roles increased from 0 to 98, representing 25% of headcount.
- Jun 17, 2026
Monthly visitors increased 89% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 5, 2026
Isomorphic Labs and Johnson & Johnson Co. enter into a cross-modality, multi-target research collaboration that combines Isomorphic Labs's AI-first drug-discovery approach with Johnson & Johnson Co.'s drug-discovery and development expertise.
- promotesOct 31, 2026
Isomorphic Labs promotes Jaderberg to president in Jan '26 after he serves as chief AI officer.
- attends_eventOct 21, 2026
Isomorphic Labs's President Max Jaderberg signs an agreement with Abu Dhabi's health authority at the Abu Dhabi Future Health Summit in United Arab Emirates on Oct 21st '26.
- is_developingOct 21, 2026
Isomorphic Labs agrees with the Department of Health-Abu Dhabi to develop a preclinical research roadmap for AI-enabled drug discovery through a 24-month collaboration using Abu Dhabi’s clinical and genomic data within its Trusted Research Environment.
- is_developingAug 11, 2026
Isomorphic Labs, based in the United Kingdom, is developing AI systems designed to accelerate the identification and development of new medicines.
For institutional investors. Book with your work email.
Isomorphic Labs Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Appears On
Curated lists and screens where this company is featured.
Frequently Asked Questions
Common questions about Isomorphic Labs's valuation, stock price, and market status.
Is Isomorphic Labs a public or private company?
Isomorphic Labs is a private company.
What is the current stock price of Isomorphic Labs?
Isomorphic Labs is a private company, so its shares have no public market price. Caplight tracks Isomorphic Labs's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Isomorphic Labs worth (valuation)?
Isomorphic Labs's valuation is estimated at $17.5B based on funding round data.
Can I buy Isomorphic Labs stock?
Isomorphic Labs shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Isomorphic Labs's last funding round?
Isomorphic Labs's most recent funding round was Series B on May 12, 2026.
Who are the main investors in Isomorphic Labs?
Key investors in Isomorphic Labs include Thrive Capital.
Will Isomorphic Labs IPO soon?
No public IPO plans have been announced for Isomorphic Labs.
How can I track Isomorphic Labs secondary market activity?
Caplight tracks bids, offers, and trades in Isomorphic Labs's shares on secondary markets.